Aligos Therapeutics, Inc. (ALGS) vs Merck & Co., Inc. (MRK)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ALGS | MRK | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | NANO | MEGA |
| Listing | Nasdaq CM | NYSE |
| Country | United States | United States |
| Theme | glp-1-and-obesity | oncology |
| Price and returns | ||
| Last close | $4.65 | $140.61 |
| Return · 1 week | −3.93% | −2.10% |
| Return · 1 month | −16.06% | −5.43% |
| Return · 3 months | +9.41% | +6.67% |
| Return · year to date | −49.07% | +33.07% |
| Return · 1 year | −52.41% | +62.34% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −66.03% | −10.39% |
| 52-week high | $13.69 | $156.92 |
| 52-week low | $3.98 | $82.01 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $29.04M | $346.91B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $230.64K | $1.24B |
| Employees | 82 | 73,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 115.56× |
| Price to earnings · forward | n/a (negative forward earnings) | 15.62× |
| Price to sales | 1.06× | 5.40× |
| Price to book | 1.04× | 8.57× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 13.82× |
| Enterprise value to revenue | 0.20× | 6.00× |
| PEG ratio | — | 2.59 |
| Earnings per share · trailing | -7.45 | 1.26 |
| Profitability | ||
| Gross margin | — | 72.97% |
| Operating margin | −6.80% | −0.24% |
| Profit margin | −241.01% | 4.77% |
| Return on equity | −113.59% | 6.96% |
| Return on assets | −49.12% | 11.87% |
| Growth | ||
| Revenue growth | +2778.50% | +5.10% |
| Balance sheet and payout | ||
| Debt / equity (%) | 10.99 | 128.41 |
| Current ratio | 2.19 | 1.32 |
| Dividend yield | 0.00% | 2.38% |
| Payout ratio | — | 266.67% |
| Trend and volatility | ||
| RSI · 14 | 33.14 | 42.46 |
| ADX · 14 | 16.43 | 16.51 |
| 50-day average | $5.70 | $146.74 |
| 200-day average | $6.32 | $126.01 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 7.93% | 3.41% |
The full ALGS analysis
Everything this table leaves out for Aligos Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ALGS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ALGS analysisThe full MRK analysis
Everything this table leaves out for Merck & Co., Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the MRK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full MRK analysis